Anti-IL-22R antibodies
Assigneeargenx BV
InventorsChristophe Frederic Jerome Blanchetot, Birgitte Ursø, Tine Skak-Nielsen, Malene Bertelsen, Sebastian Van Der Woning, Michael Saunders, Johannes Joseph Wilhelmus De Haard
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.
Claims26
A method of treating a subject having a skin disorder, comprising administering to the subject a therapeutically effective amount of an antibody or an antigen binding fragment thereof, which binds to human interleukin 22 receptor protein (IL-22R), wherein
- the antibody or antigen binding fragment thereof comprises a heavy chain variable domain (VH) and a light chain variable domain (VL), the VH comprising a combination of variable heavy chain CDR sequences:
- HCDR3 comprising SEQ ID NO:
- 6;
- HCDR2 comprising SEQ ID NO:
- 36;
- and HCDR1 comprising SEQ ID NO:
- 34, and the VL comprising a combination of variable light chain CDR sequences:
- LCDR3 comprising SEQ ID NO:
- 54;
- LCDR2 comprising SEQ ID NO:
- 47;
- and LCDR1 comprising SEQ ID NO:
- 16,
- thereby treating the subject.
A method of treating a subject having a skin disorder, comprising administering to the subject a therapeutically effective amount of an antibody or an antigen binding fragment thereof, which binds to human interleukin 22 receptor protein (IL-22R), wherein the antibody comprises a heavy chain comprising a heavy chain variable domain (VH) and a light chain comprising a light chain variable domain (VL), the VH comprising the amino acid sequence of SEQ ID NO:
- 63 and the VL comprising the amino acid sequence of SEQ ID NO:
- 64, thereby treating the subject.
A method of treating a subject having atopic dermatitis, comprising administering to the subject a therapeutically effective amount of an antibody or an antigen binding fragment thereof, which binds to human interleukin 22 receptor protein (IL-22R), wherein the antibody or antigen-binding fragment comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:
- 67 and wherein the light chain comprises the amino acid sequence of SEQ ID NO:
- 68, thereby treating the subject.
Dependencies are inferred from the claim text.